Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7112)	9/26/2002 10:05:44 AM
From: quidditch	Read Replies (2) \| Respond to of 52153

President Bush nominated Mark McClellan Sept. 25 to be the next FDA Commissioner, as expected (see our Sept. 25 report). He has the backing of the pharmaceutical and biotech industries, and is also likely to be approved by Sen. Kennedy (D-MA), whose committee must confirm the nomination before it is sent to the full Senate for passage. We believe McClellan is likely to be confirmed before Congress adjourns for the year in mid-October. With a Commissioner in place, FDA is more likely to pursue reforms that could improve approval times and eliminate unnecessary regulation, in our view. Interesting Globe article--McClellan the gatekeeper for previous nominees for the position for which he is now nominated. What is the feeling of the thread as to his lack of previous pharma/product safety background, which his opponents may use as a negative? Isn't that what the AC's and full FDA review are for? In my view, his big picture focus on health care policy is not such a bad qualification, even if it may result in some of our oxes being gored. quid